SCHEMBL8087620

SCHEMBL8087620

COc1ccc(C(C)NC(=O)c2cc(-c3cc(C)cc(F)c3)cnc2-c2ccc(F)nc2)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 7/20 0.55
HCRTR2 O43614 7/20 0.55
CTSA P10619 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ROCK1 Q13464 3/20 0.43
ROCK2 O75116 3/20 0.43
HPGD P15428 1/20 0.42
ABCB1 P08183 2/20 0.41
HTR1A P08908 1/20 0.39
OPRM1 P35372 1/20 0.39
DRD3 P35462 1/20 0.39
HTR2B P41595 1/20 0.39
KCNH2 Q12809 1/20 0.39
ABCC1 P33527 1/20 0.38
MAP4K4 O95819 1/20 0.38
PRKCG P05129 1/20 0.38
CDK1 P06493 1/20 0.38
PRKACA P17612 1/20 0.38
RPS6KB1 P23443 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8082671 0.87 HCRTR2 (0.51) HCRTR1HCRTR2SMN1; SMN2ROCK1ROCK2
SCHEMBL2279797 0.77 HCRTR2 (0.76) HCRTR1HCRTR2SMN1; SMN2HTR1AOPRM1
SCHEMBL12373197 0.77 HCRTR2 (0.45) HCRTR1HCRTR2ROCK1ROCK2MAPK1
SCHEMBL2279860 0.72 MET (0.43) HCRTR1HCRTR2RPS6KB1MAPK1
SCHEMBL3622483 0.71 HCRTR2 (1.00) HCRTR1HCRTR2HTR1AOPRM1DRD3
SCHEMBL2277007 0.69 SMN1; SMN2 (0.43) HCRTR1HCRTR2SMN1; SMN2HTR1AOPRM1
SCHEMBL8081046 0.69 HCRTR2 (0.73) HCRTR1HCRTR2HTR1AOPRM1DRD3
SCHEMBL2282140 0.67 KIT (0.49) HCRTR1HCRTR2ROCK1ROCK2PRKCG
SCHEMBL12024836 0.67 HCRTR2 (0.77) HCRTR1HCRTR2HTR1AOPRM1DRD3
SCHEMBL8086304 0.67 HCRTR2 (0.72) HCRTR1HCRTR2SMN1; SMN2HTR1AOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301140-A1 Pyridine Carboxamide orexin Receptor Antagonists BERGMAN JEFFREY M (US) 2011-12-08 US disclosed
US-20110301140-A1 Pyridine Carboxamide orexin Receptor Antagonists BERGMAN JEFFREY M (US) 2011-12-08 US disclosed
US-8003797-B2 Pyridine carboxamide orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-08-23 US disclosed
US-8003797-B2 Pyridine carboxamide orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-08-23 US disclosed
US-20100197652-A1 PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK & CO., INC. 2010-08-05 US disclosed
US-20100197652-A1 PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK & CO., INC. 2010-08-05 US disclosed
WO-2009020642-A1 PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197652-A1 PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R HCRTR1 2/4885HCRTR2 1/4885CTSA 418/4885
US-20110301140-A1 Pyridine Carboxamide orexin Receptor Antagonists HCRTR2, HCRTR1, NPY1R HCRTR1 2/4885HCRTR2 1/4885CTSA 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.